GlassScriptPhysician profile
Ben G Lazarus
NPI 1922196518
$2,341.49
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $606 · 2020: $185 · 2021: $219 · 2022: $620 · 2023: $558 · 2024: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $711.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $826.38 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $331.61 | 2019-2024 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $210.77 | 2019-2024 | Trulance |
| Celgene Corporation | $159.07 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $130.85 | 2019-2022 | |
| Pfizer INC. | $81.60 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $77.48 | 2019-2022 | |
| Genzyme Corporation | $69.32 | 2022-2023 | |
| Nestle Healthcare Nutrition INC. | $68.08 | 2021-2023 | |
| Intercept Pharmaceuticals, INC. | $64.51 | 2019-2023 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $61.73 | 2022-2023 | Dupixent |
| Ardelyx, INC. | $45.76 | 2023 | Ibsrela |
| Shionogi INC | $28.26 | 2019 | |
| Amgen INC. | $27.64 | 2023 | Amjevita, Avsola |
| Ironwood Pharmaceuticals, INC | $24.98 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $23.28 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $21.51 | 2024 | Bylvay |
| E.R. Squibb & Sons, L.L.C. | $20.39 | 2022 | |
| Fresenius Kabi USA, LLC | $19.68 | 2023 | |
| Daiichi Sankyo INC. | $18.64 | 2019 | |
| Qol Medical, LLC | $15.05 | 2019 | |
| Boston Scientific Corporation | $14.90 | 2024 | Cre Pro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ben Lazarus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.